{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:50:51Z","timestamp":1767135051414,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd011205","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T00:00:00Z","timestamp":1470096000000}}],"reference-count":108,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011205.pub2","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T14:28:10Z","timestamp":1470148090000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Guanylate cyclase stimulators for pulmonary hypertension"],"prefix":"10.1002","volume":"2016","author":[{"given":"Andrew J","family":"Wardle","sequence":"first","affiliation":[{"name":"Imperial College London; Cardiology, Hammersmith Hospital; Norfolk Place London UK W2 1PG"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J","family":"Seager","sequence":"additional","affiliation":[{"name":"Imperial College London; Academic Section of Vascular Surgery; Charing Cross Hospital Fulham Palace Road London UK W6 8RF"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Wardle","sequence":"additional","affiliation":[{"name":"Queens Medical Centre; Nottingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert MR","family":"Tulloh","sequence":"additional","affiliation":[{"name":"Bristol Royal Hospital for Children and Bristol Heart Institute; Congenital Heart Disease; Upper Maudlin Street Bristol UK BS2 8BJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J Simon R","family":"Gibbs","sequence":"additional","affiliation":[{"name":"Imperial College London; National Heart & Lung Institute; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,8,2]]},"reference":[{"issue":"8","key":"10.1002\/14651858.CD011205.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.cardfail.2014.06.035","article-title":"Riociguat for HF with pulmonary hypertension (PH): Post-hoc analysis of LEPHT by baseline pulmonary vascular resistance (PVR) and pulmonary vascular gradient (PVG)","volume":"20","author":"Bonderman","year":"2014","journal-title":"Journal of Cardiac Failure"},{"issue":"5","key":"10.1002\/14651858.CD011205.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","article-title":"Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study","volume":"128","author":"Bonderman","year":"2013","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0003|cit3","unstructured":"Bonderman D Ghio S Felix SB Ghofrani HA Michelakis ED Mitrovic V Riociguat improves pulmonary arterial compliance in patients with pulmonary hypertension due to systolic left ventricular dysfunction: Results from a post-hoc analysis of the phase IIB double-blind, randomized, placebo-controlled, dose-ranging hemodynamic LEPHT study American Heart Association Scientific Sessions; 2013 Nov 16-20; Dallas 2013 A17234"},{"issue":"8","key":"10.1002\/14651858.CD011205.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/eurjhf\/hfs071","article-title":"Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design","volume":"14","author":"Ghio","year":"2012","journal-title":"European Journal of Heart Failure"},{"issue":"23","key":"10.1002\/14651858.CD011205.pub2-BIB0005|cit5","first-page":"2789","article-title":"Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT)","volume":"126","author":"Semigran","year":"2012","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD011205.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1378\/chest.14-0106","article-title":"Acute hemodynamic effects of riociguat in patients with pulmonary hypertension","volume":"146","author":"Bonderman","year":"2014","journal-title":"Chest"},{"issue":"suppl 1","key":"10.1002\/14651858.CD011205.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"620 [P3321]","DOI":"10.1093\/eurheartj\/eht309.P3321","article-title":"Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE-1): A randomized, double-blind, placebo-controlled, single-dose study","volume":"34","author":"Bondermann","year":"2013","journal-title":"European Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD011205.pub2-BIB0009|cit8","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1183\/09031936.00105914","article-title":"PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in PAH","volume":"45","author":"Galile","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0008|cit9","first-page":"A3530","article-title":"A placebo-controlled, double-blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS)","volume":"187","author":"Gali\u00e8","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD011205.pub2-BIB0010|cit10","first-page":"A3534","article-title":"Efficacy of riociguat in pretreated versus treatment-naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT-1 study","volume":"187","author":"Humbert","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0011|cit11","unstructured":"Gali\u00e8 N Grimminger F Gr\u00fcnig E Humbert M Jing Z-C Keogh AM Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT-1 study [Abstract] European Respiratory Society 23rd Annual Congress; 2013 Sep 7-11; Barcelona 2013 346s [1784]"},{"issue":"4","key":"10.1002\/14651858.CD011205.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1027A","DOI":"10.1378\/chest.1462799","article-title":"Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study (PATENT-1) [Abstract]","volume":"142","author":"Ghofrani","year":"2012","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD011205.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0014|cit14","first-page":"A2370","article-title":"Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: long-term safety, tolerability, and efficacy [Abstract]","volume":"185","author":"Ghofrani","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0017|cit15","unstructured":"Grunig E Gaile N Humbert M Keogh AM Langleben D Rubin LJ Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study European Respiratory Society Annual congress, 2013 Sept 7-11, Barcelona, Spain 2013"},{"issue":"Suppl 57","key":"10.1002\/14651858.CD011205.pub2-BIB0015|cit16","first-page":"346s [1783]","article-title":"Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study [Abstract]","volume":"42","author":"Gr\u00fcnig","year":"2013","journal-title":"European Respiratory Society 23rd Annual Congress; 2013 Sep 7-11; Barcelona"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0016|cit17","doi-asserted-by":"crossref","unstructured":"Gr\u00fcnig E Sikirica M Curram J Davie N Gohfrani HA Riociguat for the treatment of patients with pulmonary arterial hypertension (PAH): Responder analysis of who functional class iii patients from the patent-1 study Value in Health. Conference: ISPOR 16th Annual European Congress Dublin Ireland. Conference Start: 20131102 Conference End: 20131106 November 2013","DOI":"10.1016\/j.jval.2013.08.1206"},{"issue":"1","key":"10.1002\/14651858.CD011205.pub2-BIB0018|cit18","first-page":"44","article-title":"Comparison of hemodynamic parameters in treatment-naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT-1 study","volume":"34","author":"Jing","year":"2013","journal-title":"European Heart Journal."},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD011205.pub2-BIB0020|cit19","first-page":"A3532","article-title":"Baseline characteristics and response to treatment in pretreated versus treatment-naive patients with pulmonary arterial hypertension (PAH) in the phase III PATENT-1 study","volume":"187","author":"Langleben","year":"2013","journal-title":"American Journal of respiratory and Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011205.pub2-BIB0019|cit20","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.healun.2014.12.001","article-title":"Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study","volume":"34","author":"Langleben","year":"2015","journal-title":"Journal of Heart and Lung Transplantation"},{"issue":"(3 Suppl)","key":"10.1002\/14651858.CD011205.pub2-BIB0021|cit21","first-page":"513A","article-title":"Long-term riociguat treatment in PAH patients in WHOfunctional Class (FC) I\/II Versus FC III\/IV at baseline: results from the 12-week phase III PATENT-1 study and PATENT-2open-label extension","volume":"145","author":"Meyer","year":"2013","journal-title":"Chest"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Meyer G Gali\u00e8 N Grimminger F Gr\u00fcnig E Humbert M Jing Z-C Long-term riociguat treatment in PAH patients in WHO functional class (FC) I\/II versus FC III\/IV at baseline: results from the 12-week phase III PATENT-1 study and PATENT-2 open-label extension [Abstract] American College of Chest Physicians World Congress; 2014 Oct 25-30; Austin 2014 513A","DOI":"10.1378\/chest.1824389"},{"issue":"4","key":"10.1002\/14651858.CD011205.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1024A","DOI":"10.1378\/chest.1783307","article-title":"Riociguat for the treatment of pulmonary arterial hypertension(PAH): 1-Year results from the PATENT-2 long-term extension study","volume":"144","author":"Rubin","year":"2013","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD011205.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1183\/09031936.00090614","article-title":"Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)","volume":"45","author":"Rubin","year":"2015","journal-title":"European Respiratory Society"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0025|cit25","doi-asserted-by":"crossref","unstructured":"Rubin RJ Gaile N Grimminger F Grunig E Humbert MJ Jing Z-C Riociguat for the treatment of pulmonary arterial hypertension (pah): a phase Iii long-term extension study (patent-2) American Thoracic Society International Conference, May 17-22, 2013, Philadelphia, Pennsylvania, USA 2013","DOI":"10.1378\/chest.1783307"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0026|cit26","unstructured":"D'Armini AM Ghofrani H-A Kim NH Mayer E Simonneau G Wilkins MR Riociguat for the treatment of inoperable CTEPH or persistent\/recurrent PH after pulmonary endarterectomy (PEA): A responder analysis from the phase III CHEST-1 study [Abstract] European Respiratory Society 23rd Annual Congress; 2013 Sep 7-11; Barcelona 2013 543s [P2598]"},{"issue":"3","key":"10.1002\/14651858.CD011205.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.healun.2015.02.003","article-title":"Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study","volume":"34","author":"D'Armini","year":"2015","journal-title":"Journal of Heart and Lung Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD011205.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1023A","DOI":"10.1378\/chest.1462924","article-title":"Riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: a randomized, double-blind, placebo-controlled study (CHEST-1) [Abstract]","volume":"142","author":"Ghofrani","year":"2012","journal-title":"Chest"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0029|cit29","unstructured":"Ghofrani H-A Grimminger F Hoeper MM Kim NH Mayer E Simonneau G Impact of riociguat on health-related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)[Abstract] European Respiratory Society 23rd Annual Congress; 2013 Sep 7-11; Barcelona 2013 701s [P3418]"},{"issue":"4","key":"10.1002\/14651858.CD011205.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0031|cit31","unstructured":"Ghofrani HA Grimminger F Hoeper M Kim N Mayer E Simonneau G Impact of riociguat on health-related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) European Respiratory Society Annual Congress, 2013 Sept 7-11, Barcelona, Spain 2013"},{"issue":"4","key":"10.1002\/14651858.CD011205.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1183\/09031936.00182909","article-title":"Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study","volume":"36","author":"Ghofrani","year":"2010","journal-title":"European Respiratory Journal"},{"issue":"suppl 1","key":"10.1002\/14651858.CD011205.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/eurheartj\/eht308.1066","article-title":"Comparison of hemodynamic parameters in patients with inoperable and persistent\/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST-1 study","volume":"34","author":"Jansa","year":"2013","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD011205.pub2-BIB0034|cit34","first-page":"187","article-title":"Comparison of hemodynamic parameters in patients with inoperable and persistent\/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST-1 study","volume":"34","author":"Jansa","year":"2013","journal-title":"European Heart Journal."},{"issue":"4_MeetingAbstra","key":"10.1002\/14651858.CD011205.pub2-BIB0036|cit35","doi-asserted-by":"crossref","first-page":"1023A","DOI":"10.1378\/chest.1783236","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1-year results from the CHEST-2 long-term extension study [Abstract]","volume":"144","author":"Simonneau","year":"2013","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD011205.pub2-BIB0037|cit36","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1183\/09031936.00087114","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)","volume":"45","author":"Simonneau","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"4 Meeting Abstr","key":"10.1002\/14651858.CD011205.pub2-BIB0035|cit37","doi-asserted-by":"crossref","first-page":"1023A","DOI":"10.1378\/chest.1783236","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 1-year results from the CHEST-2 long-term extension study [Abstract]","volume":"144","author":"Simonneau","year":"2013","journal-title":"Chest"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD011205.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"535B","DOI":"10.1378\/chest.1824508","article-title":"Long-term riociguat treatment in inoperable and persistent\/recurrent CTEPH patients in WHO functional class (FC) I\/II versus FC III\/IV at baseline: results from the 16-week phase III CHEST-1 study and CHEST-2 open-label extension [Abstract]","volume":"145","author":"Wang","year":"2014","journal-title":"Chest"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0039|cit39","unstructured":"Aschauer S Duca F Bachmnn A Kammerlander A Zotter-Tufaro C Mascherbauer J Riociguat treatment for patients with pulmonary hypertension due to heart failure with preserved ejection fraction European Heart Journal. Conference: European Society of Cardiology, ESC Congress 2015 London United Kingdom. Conference Start: 20150829 Conference End: 20150902 Conference Publication: (var.pagings). 36 (pp 315)"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0040|cit40","unstructured":"Aschauer SS Duca F Bachmann A Kammerlander A Zotter-Tufaro C Mascherbauer J Riociguat treatment for patients with pulmonary hypertension due to heart failure with preserved ejection fraction European Journal of Heart Failure. Conference: Heart Failure 2015 and the 2nd World Congress on Acute Heart Failure Seville Spain. Conference Start: 20150523 Conference End: 20150526. May 2015 Conference Publication: (var.pagings). 17 (pp 278-279"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0041|cit41","first-page":"4068","article-title":"Pharmacokinetic (PK) interaction of ketoconazole (KC), clarithromycin (CM) and midazolam (MZ) with riociguat","volume":"42","author":"Becker","year":"2013","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0042|cit42","first-page":"Conference Publ","article-title":"Efficacy and safety of riociguat in patients with pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD)","volume":"74","author":"Denton","year":"June 2015.","journal-title":"Annals of the Rheumatic Diseases. Conference: Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR 2015 Rome Italy. Conference Start: 20150610 Conference End: 20150613."},{"key":"10.1002\/14651858.CD011205.pub2-BIB0043|cit43","first-page":"46","article-title":"Change of right heart size and function by long-term therapy with riociguat in patients with PAH and CTEPH","volume":"Conference Publ","author":"Egenlauf","journal-title":"European Respiratory Journal. Conference: European Respiratory Society Annual Congress 2015 Amsterdam Netherlands. Conference Start: 20150926 Conference End: 20150930."},{"issue":"8","key":"10.1002\/14651858.CD011205.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/0091270008319793","article-title":"Single-Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Stimulator BAY 63-2521: An Ascending-DoseStudy in Healthy Male Volunteers","volume":"48","author":"Frey","year":"2008","journal-title":"Journal of Clinical Pharmacology"},{"issue":"suppl 1","key":"10.1002\/14651858.CD011205.pub2-BIB0047|cit45","doi-asserted-by":"crossref","first-page":"P15","DOI":"10.1186\/1471-2210-9-S1-P15","article-title":"Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (bay 63-2521)","volume":"9","author":"Frey","year":"2009","journal-title":"BMC Pharmacology"},{"issue":"7","key":"10.1002\/14651858.CD011205.pub2-BIB0045|cit46","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1177\/0091270010378119","article-title":"Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study","volume":"51","author":"Frey","year":"2011","journal-title":"Journal of Clinical Pharmacology"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD011205.pub2-BIB0046|cit47","first-page":"A3349","article-title":"Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521): results of a randomized, controlled trial [Abstract]","volume":"181","author":"Frey","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0049|cit48","doi-asserted-by":"crossref","unstructured":"Frey R Muck W Unger S Reber M Kratzschmar J Becker C No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin 5th International Conference on cGMP: Generators, Effectors and Therapeutic Implications; 2011 24-26 June; Halle 2011 P25","DOI":"10.1186\/1471-2210-11-S1-P25"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0048|cit49","doi-asserted-by":"crossref","unstructured":"Frey R M\u00fcck W Unger S Reber M Kr\u00e4tzschmar J Becker C No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin [Abstract] European Respiratory Society 21st Annual Congress; 2011 Sep 24-28; Amsterdam 2011 724s [P3977]","DOI":"10.1186\/1471-2210-11-S1-P25"},{"issue":"(Suppl 1)","key":"10.1002\/14651858.CD011205.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1186\/1471-2210-9-S1-S14","article-title":"Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)","volume":"9","author":"Ghofrani","year":"2009","journal-title":"BMC Pharmacology"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0051|cit51","unstructured":"Ghofrani HA Hoeper MM Halank M Meyer FJ Staehler G Behr J A phase 2 study of the soluble guanylate cyclase stimulator riociguat in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension Circulation. Conference: World Congress of CardiologyScientific Sessions 2010, WCC 2010 Beijing China. Conference Start: 20100616 Conference End: 20100619. Jul 2010 2"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1183\/09031936.00182909","article-title":"Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study","volume":"36","author":"Ghofrani","year":"2010","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0053|cit53","doi-asserted-by":"crossref","unstructured":"Ghofrani HA Staehler G Gruenig E Halank M Mitrovic V Unger S The Effect Of The Soluble Guanylate Cyclase Stimulator Riociguat On Hemodynamics In Patients With Pulmonary Hypertension Due To Chronic Obstructive Pulmonary Disease [Abstract] American Journal of Respiratory and Critical CareMedicine. Conference: American Thoracic Society InternationalConference, ATS 2011 Denver, CO United States. ConferenceStart: 20110513 Conference End: 20110518 May 2011","DOI":"10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A6127"},{"issue":"4","key":"10.1002\/14651858.CD011205.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1183\/09031936.00039808","article-title":"First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension","volume":"33","author":"Grimminger","year":"2009","journal-title":"European Respiratory Journal"},{"issue":"10","key":"10.1002\/14651858.CD011205.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.cjca.2015.07.095","article-title":"Riociguat for chronic thromboembolic pulmonary hypertension-initial experience","volume":"31","author":"Haddad","year":"2015","journal-title":"Canadian Journal of Cardiology."},{"issue":"8","key":"10.1002\/14651858.CD011205.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cardfail.2015.06.226","article-title":"Riociguat for chronic thromboembolic pulmonary hypertension-initial experience","volume":"21","author":"Haddad","year":"2015","journal-title":"Journal of Cardiac Failure"},{"issue":"suppl 59","key":"10.1002\/14651858.CD011205.pub2-BIB0057|cit57","first-page":"OA4999","article-title":"Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry","volume":"46","author":"Halank","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD011205.pub2-BIB0058|cit58","first-page":"853","article-title":"Riociguat for patients with pulmonary hypertension associated with interstitial lung disease","volume":"41","author":"Hoeper","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011205.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1183\/09031936.00213911","article-title":"Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial","volume":"41","author":"Hoeper","year":"2013","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0060|cit60","unstructured":"Parley EL Masamune H Hoye WL Rubin LJ Gladwin MT Nebulized inhaled nitrite (AIR001) for pulmonary arterial hypertension: Studies to determine safety, pharmacokinetics, and maximum tolerated dose, lack of pharmacodynamic interaction with sildenafil and optimal nebulizer device 5th International Meeting on the Role of Nitrite and Nitrate in Physiology, Pathophysiology, and Therapeutics; 2013 May 4-5; Pittsburgh 2013 S41 2"},{"issue":"2","key":"10.1002\/14651858.CD011205.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40119-015-0046-y","article-title":"Early observations on the use of riociguat in a large, metropolitan pulmonary arterial hypertension\/chronic thromboembolic pulmonary hypertension treatment center","volume":"4","author":"Sulica","year":"2015","journal-title":"Cardiology and Therapy"},{"issue":"6","key":"10.1002\/14651858.CD011205.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1017\/S1047951115001961","article-title":"Feasibility and safety of cardiopulmonary exercise testing in children with pulmonary hypertension","volume":"26","author":"Abumehdi","year":"2015","journal-title":"Cardiology in the Young"},{"issue":"4","key":"10.1002\/14651858.CD011205.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1056\/NEJMe1306684","article-title":"Riociguat for pulmonary hypertension - a glass half full","volume":"369","author":"Archer","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011205.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0065|cit65","unstructured":"Bayer Pharmaceuticals 2014 Price List www.bayer.co.uk\/html\/pdf\/Pharma\/190614_Official_List_Prices.pdf"},{"issue":"16","key":"10.1002\/14651858.CD011205.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1161\/CIRCULATIONAHA.106.661041","article-title":"Predictors of outcome in chronic thromboembolic pulmonary hypertension","volume":"115","author":"Bonderman","year":"2007","journal-title":"Circulation"},{"issue":"18","key":"10.1002\/14651858.CD011205.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1093\/eurheartj\/ehq245","article-title":"Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure","volume":"31","author":"Damy","year":"2010","journal-title":"European Heart Journal"},{"issue":"2-3","key":"10.1002\/14651858.CD011205.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0005-2728(99)00024-9","article-title":"Guanylate cyclase and the NO\/cGMP signalling pathway","volume":"1411","author":"Denninger","year":"1999","journal-title":"Biochimica et Biophysica Acta"},{"issue":"2","key":"10.1002\/14651858.CD011205.pub2-BIB0069|cit69","first-page":"163","article-title":"Riociguat recommended by CHMP for approval in the WU for use in two forms of pulmonary hypertension","volume":"10","author":"Dowdall","year":"2014","journal-title":"Future Cardiology"},{"issue":"25 Suppl","key":"10.1002\/14651858.CD011205.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"D60","DOI":"10.1016\/j.jacc.2013.10.031","article-title":"Updated treatment algorithm of pulmonary arterial hypertension","volume":"62","author":"Gali\u00e8","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl.58","key":"10.1002\/14651858.CD011205.pub2-BIB0071|cit71","first-page":"2916","article-title":"The AMBITION study: design and results","volume":"44","author":"Gali\u00e8","year":"2014","journal-title":"European Respiratory Journal"},{"issue":"12 Suppl","key":"10.1002\/14651858.CD011205.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"68S","DOI":"10.1016\/j.jacc.2004.02.031","article-title":"Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension","volume":"43","author":"Ghofrani","year":"2004","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD011205.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(16)30019-4","article-title":"Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial","volume":"4","author":"Ghofrani","year":"2016","journal-title":"The Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0074|cit74","unstructured":"GRADE Working Group, McMaster GRADEpro GDT 2014"},{"issue":"12","key":"10.1002\/14651858.CD011205.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/nbt1213-1064b","article-title":"First-in-class guanylate cyclase stimulator approved for PAH","volume":"31","author":"Guha","year":"2013","journal-title":"Nature Biotechnology"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0076|cit76","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"136","key":"10.1002\/14651858.CD011205.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1183\/16000617.00001015","article-title":"Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension","volume":"24","author":"Hoeper","year":"2015","journal-title":"European Respiratory Review"},{"issue":"1","key":"10.1002\/14651858.CD011205.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/thoraxjnl-2015-207170","article-title":"The molecular targets of approved treatments for pulmonary arterial hypertension","volume":"71","author":"Humbert","year":"2016","journal-title":"Thorax"},{"issue":"25 Suppl","key":"10.1002\/14651858.CD011205.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"D117","DOI":"10.1016\/j.jacc.2013.10.028","article-title":"Pediatric pulmonary hypertension","volume":"62","author":"Ivy","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"25","key":"10.1002\/14651858.CD011205.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.jacc.2008.08.059","article-title":"Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT(Bosentan effects in iNopErable forms of chronIc thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial","volume":"52","author":"Jais","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD011205.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/S0003-4975(03)00828-2","article-title":"Pulmonary endarterectomy: experience and lessons learned in 1,500 cases","volume":"76","author":"Jamieson","year":"2003","journal-title":"Annals of Thoracic Surgery"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD011205.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.jacc.2009.04.016","article-title":"Interventional and surgical modalities of treatment in pulmonary hypertension","volume":"54","author":"Keogh","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD011205.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1164\/rccm.201203-0383OC","article-title":"Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension","volume":"186","author":"Ling","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011205.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jtcvs.2010.11.024","article-title":"Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry","volume":"141","author":"Mayer","year":"2011","journal-title":"Journal of Thoracic and Cardiovascular Surgery"},{"issue":"25 Suppl","key":"10.1002\/14651858.CD011205.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"D73","DOI":"10.1016\/j.jacc.2013.10.034","article-title":"Treatment goals of pulmonary hypertension","volume":"62","author":"McLaughlin","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD011205.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1164\/ajrccm.161.2.9906015","article-title":"Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing","volume":"161","author":"Miyamoto","year":"2000","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0087|cit87","unstructured":"Bayer Single dose study in patients with chronic obstructive pulmonary disease (COPD) associated pulmonary hypertension https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00640315"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0088|cit88","unstructured":"Bayer Long-term extension study in patients with pulmonary arterial hypertension (PATENT-2) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00863681"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0089|cit89","unstructured":"Bayer Long-term extension study in patients with chronic thromboembolic pulmonary hypertension (CHEST-2) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00910429"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0090|cit90","unstructured":"Bayer Riociguat clinical effects studied in patients with insufficient treatment response to phosphodiesterase-5 inhibitor (RESPITE) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02007629"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0091|cit91","unstructured":"Bayer Efficacy and safety of riociguat in patients with symptomatic pulmonary hypertension (PH) associated with idiopathic interstitial pneumonias (IIP) (13605RISE-IIP) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02138825"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0092|cit92","unstructured":"Bayer Efficacy and safety of riociguat in patients with systemic sclerosis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02283762"},{"issue":"9","key":"10.1002\/14651858.CD011205.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/ejhf.135","article-title":"Rationale and design of the SOluble guanylate cyclase stimulatoR in heArT failurE studies (SOCRATES)","volume":"16","author":"Pieske","year":"2014","journal-title":"European Journal of Heart Failure"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0094|cit94","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"2","key":"10.1002\/14651858.CD011205.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1378\/chest.81.2.151","article-title":"Longterm follow-up of patients with pulmonary thromboembolism: late prognosis and evolution of hemodynamic and respiratory data","volume":"81","author":"Riedel","year":"1982","journal-title":"Chest"},{"key":"10.1002\/14651858.CD011205.pub2-BIB0096|cit96","doi-asserted-by":"crossref","unstructured":"Rubin L Gali\u00e8 N Grimminger F Gr\u00fcnig E Humbert M Jing Z-C Riociguat for the treatment of pulmonary arterial hypertension (PAH): 1-year results from the PATENT-2 long-term extension study [Abstract] Chest 2013 1024A","DOI":"10.1378\/chest.1783307"},{"issue":"4","key":"10.1002\/14651858.CD011205.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1517\/13543784.2011.565048","article-title":"Riociguat for the treatment of pulmonary hypertension","volume":"20","author":"Schermuly","year":"2011","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"2","key":"10.1002\/14651858.CD011205.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00408-011-9350-z","article-title":"Clinical worsening during long-term follow-up in inoperable chronic thromboembolic pulmonary hypertension","volume":"190","author":"Scholzel","year":"2012","journal-title":"Lung"},{"issue":"8","key":"10.1002\/14651858.CD011205.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomised trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Annals of Internal Medicine"},{"issue":"25 Suppl","key":"10.1002\/14651858.CD011205.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated clinical classification of pulmonary hypertension","volume":"62","author":"Simonneau","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD011205.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S2213-2600(16)30022-4","article-title":"Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial","volume":"4","author":"Simonneau","year":"2016","journal-title":"The Lancet Respiratory Medicine"},{"issue":"20","key":"10.1002\/14651858.CD011205.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD011205.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1253\/circj.CJ-15-1212","article-title":"Multiple Beneficial Effects of Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension","volume":"80","author":"Tatebe","year":"2016","journal-title":"Circulation Journal: official journal of the Japanese Circulation Society"},{"issue":"5","key":"10.1002\/14651858.CD011205.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1183\/09031936.00072709","article-title":"Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation","volume":"35","author":"Thenappan","year":"2010","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD011205.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jtcvs.2005.07.033","article-title":"Outcomes of pulmonary endarterectomy for treatment of extreme thromboembolic pulmonary hypertension","volume":"131","author":"Thistlethwaite","year":"2006","journal-title":"Journal of Thoracic and Cardiovascular Surgery"},{"issue":"9","key":"10.1002\/14651858.CD011205.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/archdischild-2012-303333","article-title":"The utility of sildenafil in pulmonary arterial hypertension: a focus on bronchopulmonary dysplasia","volume":"98","author":"Wardle","year":"2013","journal-title":"Archives of Disease in Childhood"},{"issue":"2","key":"10.1002\/14651858.CD011205.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00246-012-0598-8","article-title":"Evolving management of pediatric pulmonary arterial hypertension: impact of phosphodiesterase inhibitors","volume":"34","author":"Wardle","year":"2013","journal-title":"Pediatric Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD011205.pub2-BIB0108|cit108","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011205","article-title":"Guanylate cyclase stimulators for pulmonary hypertension","author":"Wardle","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD011205.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T12:50:12Z","timestamp":1633870212000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011205.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,8,2]]},"references-count":108,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011205.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,2]]}}}